Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Despite the broadened scope of CFIUS to review transactions, Morrison & Foerster partner Thomas T.H. Chou advised in the South China Morning Post article “Leading Chinese biotech firm Wuxi AppTec says US hurdles will not dim acquisition appetite” that Chinese firms are still actively seeking to make deals with U.S. companies.

Leading Chinese biotech firm Wuxi AppTec says US hurdles will not dim acquisition appetite

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Despite the broadened scope of CFIUS to review transactions, Morrison & Foerster partner Thomas T.H. Chou advised in the South China Morning Post article “<a target="_blank" href="https://www.scmp.com/business/article/2175888/leading-chinese-biotech-firm-wuxi-apptec-says-us-hurdles-will-not-dim">Leading Chinese biotech firm Wuxi AppTec says US hurdles will not dim acquisition appetite</a>” that Chinese firms are still actively seeking to make deals with U.S. companies.“U.S. biotech companies generally remain quite interested in partnering with Chinese companies because of the enormous market potential and the recognition that the Chinese are increasingly innovative. That is why the industry trade groups are trying to find ways to help address U.S. national security concerns without cutting off the U.S. from the innovations that are occurring in China,” he said.

Leading Chinese biotech firm Wuxi AppTec says US hurdles will not dim acquisition appetite